米食品医薬品局(FDA)が放射性医薬品iobenguane I 131 (Azedra)について、切除不能な12歳以上の副腎腫瘍患者(褐色細胞腫または傍神経節腫瘍)に対する適応を承認【FDA】

FDA approves first treatment for rare adrenal tumors

The U.S. Food and Drug Administration today approved Azedra (iobenguane I 131) injection for intravenous use for the treatment of adults and adolescents age 12 and older with rare tumors of the adrenal gland (pheochromocytoma or paraganglioma) that cannot be surgically removed (unresectable), have spread beyond the original tumor site and require systemic anticancer therapy. This is the first FDA-approved drug for this use.

 


 


 

コメント

Leave a comment

Your email address will not be published.


*